Scholarlink

Background <p>There is an increased interest in using proton beam radiation therapy (PBT) in Central nervous system (CNS) tumors. However, no clear information exists about the association of PBT with the overall survival (OS) of patients diagnosed with CNS tumors. The current study aims to investigate the association of PBT with the OS of patients with CNS tumors.</p> Methods <p>This study included patients from the National Cancer Database diagnosed with CNS tumors between 2004 and 2022. Multivariable Cox regression analysis was used to assess the OS. The multivariable analyses were adjusted for age at diagnosis, sex, race, RT dose, health insurance, histology, education, income, comorbidity score, surgery, chemotherapy, and year of diagnosis.</p> Results <p>Of the 162,506 patients, 5,548 (3.4%) received PBT. In the multivariable Cox regression analysis, patients who received PBT had longer OS compared to patients who received photon RT (Hazard Ratio (HR): 0.67 [95% CI: 0.64–0.71], <i>p &lt;</i> 0.001). In the subset analyses stratified by surgery, the use of PBT was associated with improved OS compared to photon RT in patients who received surgery (HR:0.76 [95% CI: 0.70–0.82], <i>p &lt;</i> 0.001) and in patients who did not receive surgery (HR: 0.61 [95% CI: 0.57–0.65], <i>p &lt;</i> 0.001). When stratified by histology, PBT was associated with improved OS compared to photon RT in patients diagnosed with astrocytoma (HR: O.65 [95% CI: 0.53–0.81], <i>p &lt;</i> 0.001), glioblastoma (HR: 0.79 [95% CI: 0.71–0.88], <i>p &lt;</i> 0.001) or other types (HR: 0.60 [95% CI: 0.37–0.98], <i>p =</i> 0.04) among patients who received surgery. PBT was also associated with improved OS compared to photon RT in patients diagnosed with astrocytoma (HR: O.44 [95% CI: 0.39–0.50], <i>p &lt;</i> 0.001), glioblastoma (HR: 0.81 [95% CI: 0.73–0.90], <i>p &lt;</i> 0.001) or other types (HR: 0.41 [95% CI: 0.28–0.60], <i>p &lt;</i> 0.001) among those who did not receive surgery.</p> Conclusions <p>Patients who received PBT had longer OS compared to patients who received photon RT (HR:0.67 [95% CI: 0.64–0.71], <i>p &lt;</i> 0.001). In the subset analyses stratified by surgery, the use of PBT was associated with improved OS compared to photon RT in patients who received surgery (HR:0.76 [95% CI: 0.70–0.82], <i>p &lt;</i> 0.001) and in patients who did not receive surgery (HR: 0.61 [95% CI: 0.57–0.65], <i>p &lt;</i> 0.001).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Proton beam radiation therapy and the overall survival of adult and pediatric patients diagnosed with central nervous system tumors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月18日

查看全文
  • Saber Amin,
  • Palwasha Amin,
  • Chi Lin

摘要

Background

There is an increased interest in using proton beam radiation therapy (PBT) in Central nervous system (CNS) tumors. However, no clear information exists about the association of PBT with the overall survival (OS) of patients diagnosed with CNS tumors. The current study aims to investigate the association of PBT with the OS of patients with CNS tumors.

Methods

This study included patients from the National Cancer Database diagnosed with CNS tumors between 2004 and 2022. Multivariable Cox regression analysis was used to assess the OS. The multivariable analyses were adjusted for age at diagnosis, sex, race, RT dose, health insurance, histology, education, income, comorbidity score, surgery, chemotherapy, and year of diagnosis.

Results

Of the 162,506 patients, 5,548 (3.4%) received PBT. In the multivariable Cox regression analysis, patients who received PBT had longer OS compared to patients who received photon RT (Hazard Ratio (HR): 0.67 [95% CI: 0.64–0.71], p < 0.001). In the subset analyses stratified by surgery, the use of PBT was associated with improved OS compared to photon RT in patients who received surgery (HR:0.76 [95% CI: 0.70–0.82], p < 0.001) and in patients who did not receive surgery (HR: 0.61 [95% CI: 0.57–0.65], p < 0.001). When stratified by histology, PBT was associated with improved OS compared to photon RT in patients diagnosed with astrocytoma (HR: O.65 [95% CI: 0.53–0.81], p < 0.001), glioblastoma (HR: 0.79 [95% CI: 0.71–0.88], p < 0.001) or other types (HR: 0.60 [95% CI: 0.37–0.98], p = 0.04) among patients who received surgery. PBT was also associated with improved OS compared to photon RT in patients diagnosed with astrocytoma (HR: O.44 [95% CI: 0.39–0.50], p < 0.001), glioblastoma (HR: 0.81 [95% CI: 0.73–0.90], p < 0.001) or other types (HR: 0.41 [95% CI: 0.28–0.60], p < 0.001) among those who did not receive surgery.

Conclusions

Patients who received PBT had longer OS compared to patients who received photon RT (HR:0.67 [95% CI: 0.64–0.71], p < 0.001). In the subset analyses stratified by surgery, the use of PBT was associated with improved OS compared to photon RT in patients who received surgery (HR:0.76 [95% CI: 0.70–0.82], p < 0.001) and in patients who did not receive surgery (HR: 0.61 [95% CI: 0.57–0.65], p < 0.001).